Utilisation d’une biothérapie pour du psoriasis chez un patient atteint de syndrome de Cohen
- 31 July 2020
- journal article
- editorial
- Published by Elsevier BV in Annales de Dermatologie et de Vénéréologie
- Vol. 147 (12), 880-881
- https://doi.org/10.1016/j.annder.2020.07.004
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter studyJournal of Dermatological Treatment, 2018
- Risk of infection associated with anti-TNF-α therapyExpert Review of Anti-infective Therapy, 2018
- Cohen Syndrome: Review of the LiteratureCureus, 2018
- Current biological therapies for use in HIV-positive patients with psoriasis: case report of guselkumab used and reviewDermatology Online Journal, 2018
- Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipientsMedicine, 2016
- The use of infliximab in X-linked agammaglobulinaemia associated enteropathyThe Annals of The Royal College of Surgeons of England, 2014
- Hermansky‐Pudlak Syndrome: Severe Colitis and Good Response to InfliximabJournal of Pediatric Gastroenterology and Nutrition, 2010
- Complicated granulomatous colitis in a Japanese patient with Hermansky–Pudlak syndrome, successfully treated with infliximabClinical Journal of Gastroenterology, 2009
- Adalimumab for the treatment of Crohn‐like colitis and enteritis in glycogen storage disease type IbJournal of Inherited Metabolic Disease, 2008